Key facts
- It has raised $540K; the latest was Seed Round ($540K) in Feb 2026.
- Notable investors include Almi Invest, Kjell & Märta Beijers Foundation, UU Invest.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Vascurie
- ·The full record, as it builds
Funding rounds
No funding rounds for Vascurie are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vascurie
Provider of neuro-oncology biopharmaceutical services designed for patients to improve treatment outcomes. The company targets a specific protein in the tumor's blood vessels and develops an antibody-based drug, enabling patients with aggressive brain tumors to improve treatment outcomes by targeting the vascular microenvironment of high-grade gliomas and metastases.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2025
- Ownership
- Privately Held (backing)
Vascurie doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vascurie shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vascurie in its N-PORT filings yet. We sweep new filings monthly.